{"id":"chadox1-ncov-19","safety":{"commonSideEffects":[{"rate":"50-70","effect":"Injection site pain"},{"rate":"50-60","effect":"Fatigue"},{"rate":"40-50","effect":"Headache"},{"rate":"30-40","effect":"Myalgia"},{"rate":"20-30","effect":"Fever"},{"rate":"10-20","effect":"Chills"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine uses a replication-deficient chimpanzee adenovirus (ChAdOx1) as a vector to carry genetic instructions for producing the SARS-CoV-2 spike protein. Once administered, the vector enters host cells and expresses the spike protein, which stimulates both cellular and humoral immune responses. This primes the immune system to recognize and neutralize the actual SARS-CoV-2 virus upon exposure.","oneSentence":"ChAdOx1 nCoV-19 is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene into cells to trigger an immune response against COVID-19.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:29.075Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Oxford%E2%80%93AstraZeneca_COVID-19_vaccine","title":"Oxford–AstraZeneca COVID-19 vaccine","extract":"The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant and 61% against the Delta variant."},"indications":{"approved":[{"name":"COVID-19 prevention in adults"}]},"trialDetails":[{"nctId":"NCT05283902","phase":"","title":"Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly","status":"COMPLETED","sponsor":"Federal University of Espirito Santo","startDate":"2022-03-19","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine-Preventable Diseases","enrollment":260},{"nctId":"NCT05012943","phase":"PHASE2, PHASE3","title":"The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)","status":"COMPLETED","sponsor":"Vinbiocare Biotechnology Joint Stock Company","startDate":"2021-08-15","conditions":"COVID-19 Vaccines","enrollment":19474},{"nctId":"NCT05710783","phase":"PHASE2, PHASE3","title":"Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster.","status":"COMPLETED","sponsor":"Laboratorio Avi-Mex, S.A. de C.V.","startDate":"2022-11-09","conditions":"SARS-CoV-2 Infection","enrollment":4065},{"nctId":"NCT04400838","phase":"PHASE2, PHASE3","title":"Investigating a Vaccine Against COVID-19","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-05-28","conditions":"Coronavirus","enrollment":10811},{"nctId":"NCT04324606","phase":"PHASE1, PHASE2","title":"A Study of a Candidate COVID-19 Vaccine (COV001)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-04-23","conditions":"Coronavirus","enrollment":1077},{"nctId":"NCT05571735","phase":"","title":"Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2023-04-15","conditions":"Covid-19 Pandemics, Tuberculosis","enrollment":133},{"nctId":"NCT05110911","phase":"","title":"Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-04-02","conditions":"Influenza, Human, SARS-CoV-2 Infection","enrollment":1500},{"nctId":"NCT04894435","phase":"PHASE2","title":"Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2021-05-20","conditions":"COVID-19","enrollment":669},{"nctId":"NCT05126992","phase":"","title":"EU Secondary Data Post-Authorisation Safety Study of AZD1222","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-02-18","conditions":"COVID-19, Vaccine Adverse Events of Special Interest","enrollment":5321930},{"nctId":"NCT05057897","phase":"PHASE4","title":"A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2022-01-31","conditions":"COVID-19, SARS-CoV-2","enrollment":34},{"nctId":"NCT05603052","phase":"PHASE3","title":"A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"EuBiologics Co.,Ltd","startDate":"2022-07-11","conditions":"COVID-19","enrollment":2852},{"nctId":"NCT05697705","phase":"","title":"Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-22","conditions":"COVID-19","enrollment":188814085},{"nctId":"NCT05501522","phase":"PHASE3","title":"Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2022-12-09","conditions":"COVID-19","enrollment":840},{"nctId":"NCT06597370","phase":"","title":"Immunogenicity Induced by COVID-19 Vaccines in Mexican Population","status":"COMPLETED","sponsor":"National Polytechnic Institute, Mexico","startDate":"2021-09-01","conditions":"COVID-19 Vaccine","enrollment":80},{"nctId":"NCT04973449","phase":"PHASE2, PHASE3","title":"Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-06-27","conditions":"COVID-19, SARS-CoV-2","enrollment":2843},{"nctId":"NCT05054621","phase":"PHASE2","title":"Immunogenicity of COVID-19 Vaccine on Heterologous Schedule","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-09-15","conditions":"Covid-19, Vaccine, Immunogenicity","enrollment":100},{"nctId":"NCT05572879","phase":"PHASE3","title":"A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults","status":"COMPLETED","sponsor":"EuBiologics Co.,Ltd","startDate":"2022-10-01","conditions":"COVID-19","enrollment":2600},{"nctId":"NCT05387317","phase":"PHASE3","title":"Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)","status":"WITHDRAWN","sponsor":"Murdoch Childrens Research Institute","startDate":"2024-04","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04568031","phase":"PHASE1, PHASE2","title":"Study of AZD1222 for the Prevention of COVID-19 in Japan","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-08-23","conditions":"COVID-19","enrollment":256},{"nctId":"NCT04516746","phase":"PHASE3","title":"Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-08-28","conditions":"COVID-19, SARS-CoV-2","enrollment":32450},{"nctId":"NCT05343871","phase":"PHASE4","title":"Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial","status":"COMPLETED","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2022-07-05","conditions":"COVID-19","enrollment":2354},{"nctId":"NCT04832932","phase":"","title":"The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes","status":"UNKNOWN","sponsor":"Mebo Research, Inc.","startDate":"2021-01-05","conditions":"COVID-19 Vaccines","enrollment":2000},{"nctId":"NCT06189040","phase":"PHASE4","title":"Immunogenicity After COVID-19 Vaccines in Adapted Schedules","status":"COMPLETED","sponsor":"Universiteit Antwerpen","startDate":"2021-05-26","conditions":"Coronavirus Disease 2019, COVID-19","enrollment":580},{"nctId":"NCT05052307","phase":"","title":"A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil","status":"COMPLETED","sponsor":"Hospital Moinhos de Vento","startDate":"2021-11-03","conditions":"Covid19","enrollment":4574},{"nctId":"NCT05198596","phase":"PHASE3","title":"A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2022-07-30","conditions":"COVID-19 Vaccine","enrollment":250},{"nctId":"NCT05426343","phase":"PHASE3","title":"A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2022-07-09","conditions":"COVID-19 Vaccine","enrollment":200},{"nctId":"NCT04775069","phase":"PHASE4","title":"Antibody Response to COVID-19 Vaccines in Liver Disease Patients","status":"COMPLETED","sponsor":"Humanity & Health Medical Group Limited","startDate":"2021-05-21","conditions":"Chronic Liver Disease","enrollment":232},{"nctId":"NCT04826770","phase":"","title":"Adaptive Immune Response to COVID-19 Vaccination","status":"UNKNOWN","sponsor":"University Medicine Greifswald","startDate":"2021-01-06","conditions":"SARS-CoV-2 Vaccination","enrollment":70},{"nctId":"NCT04914832","phase":"PHASE4","title":"Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death","status":"COMPLETED","sponsor":"Shabir Madhi","startDate":"2021-08-30","conditions":"COVID-19, Pneumonia, Viral","enrollment":75012},{"nctId":"NCT05188677","phase":"PHASE3","title":"Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults","status":"COMPLETED","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2022-06-13","conditions":"COVID-19","enrollment":1831},{"nctId":"NCT05710289","phase":"","title":"A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.","status":"WITHDRAWN","sponsor":"SK Bioscience Co., Ltd.","startDate":"2023-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04864561","phase":"PHASE3","title":"COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2021-04-26","conditions":"SARS-CoV-2 Virus Infection","enrollment":4034},{"nctId":"NCT05197153","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2022-01-22","conditions":"COVID-19 Vaccine","enrollment":804},{"nctId":"NCT05175950","phase":"PHASE2","title":"Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2022-01-24","conditions":"COVID-19 (Healthy Volunteers)","enrollment":770},{"nctId":"NCT05715944","phase":"PHASE3","title":"Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2","status":"COMPLETED","sponsor":"Botswana Harvard AIDS Institute Partnership","startDate":"2021-09-15","conditions":"COVID-19","enrollment":10888},{"nctId":"NCT05076227","phase":"","title":"Effect of Different SARS-CoV-2 Vaccine Schedules and Vaccination Intervals on Reactogenicity and Humoral Immunogenicity","status":"COMPLETED","sponsor":"Serge Thal","startDate":"2021-01-30","conditions":"SARS-CoV2 Infection, Immunisation Reaction, Antibody Hypersensitivity","enrollment":1206},{"nctId":"NCT04760730","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2021-07-13","conditions":"COVID-19","enrollment":100},{"nctId":"NCT04816019","phase":"PHASE1","title":"A Study of Intranasal ChAdOx1 nCOV-19","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-04-01","conditions":"Coronavirus","enrollment":42},{"nctId":"NCT05074368","phase":"NA","title":"Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2021-07-06","conditions":"Healthy Adult Volunteers","enrollment":499},{"nctId":"NCT05567471","phase":"PHASE3","title":"Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose","status":"COMPLETED","sponsor":"Bharat Biotech International Limited","startDate":"2022-02-26","conditions":"COVID-19 Respiratory Infection","enrollment":875},{"nctId":"NCT05011526","phase":"PHASE3","title":"A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2021-10-08","conditions":"Covid19 Vaccine","enrollment":1030},{"nctId":"NCT05534035","phase":"PHASE3","title":"Booster Superiority Study of PTX-COVID19-B Compared to Vaxzevria® in Adults Aged 18 Years and Older","status":"UNKNOWN","sponsor":"Everest Medicines (Singapore) Pte. Ltd.","startDate":"2023-02-03","conditions":"SARS-CoV-2 Infection","enrollment":450},{"nctId":"NCT04684446","phase":"PHASE1, PHASE2","title":"Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2021-09-15","conditions":"COVID-19","enrollment":100},{"nctId":"NCT04686773","phase":"PHASE2","title":"Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2021-03-05","conditions":"COVID-19","enrollment":100},{"nctId":"NCT05289206","phase":"NA","title":"Immune Response of an Interchangeable Booster Vaccine Against COVID-19 Among Individuals With Risk Factors for Severity","status":"UNKNOWN","sponsor":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","startDate":"2021-09-30","conditions":"Comorbidities and Coexisting Conditions, Healthy","enrollment":4446},{"nctId":"NCT05315856","phase":"","title":"Reactogenicity, Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2021-03-01","conditions":"COVID-19 Vaccination, Inflammation, Vaccine Immune Response","enrollment":120},{"nctId":"NCT04834869","phase":"","title":"COVID-19 Vaccines Safety Tracking (CoVaST)","status":"RECRUITING","sponsor":"Masaryk University","startDate":"2021-04-01","conditions":"Adverse Reaction to Vaccine, COVID19 Vaccine","enrollment":30000},{"nctId":"NCT05057936","phase":"","title":"Antibody After COVID-19 Vaccination","status":"COMPLETED","sponsor":"Bangkok Metropolitan Administration Medical College and Vajira Hospital","startDate":"2021-06-01","conditions":"Covid19, Breakthrough Infection, CKD","enrollment":140},{"nctId":"NCT05145348","phase":"","title":"Prospective Monitoring of Antibody Response Following COVID-19 Vaccination in Patients With Down Syndrome.","status":"UNKNOWN","sponsor":"UMC Utrecht","startDate":"2021-02-03","conditions":"Down Syndrome, SARS-CoV-2 Vaccination","enrollment":640},{"nctId":"NCT05097053","phase":"PHASE4","title":"A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19","status":"UNKNOWN","sponsor":"Taoyuan General Hospital","startDate":"2021-10-07","conditions":"COVID-19 Vaccine","enrollment":200},{"nctId":"NCT05133609","phase":"PHASE1, PHASE2","title":"COVID-19 VACCINE SAFETY AND EFFECTIVENESS","status":"UNKNOWN","sponsor":"Federal University of Espirito Santo","startDate":"2021-01-15","conditions":"SARS-CoV-2 Infection","enrollment":550},{"nctId":"NCT04540393","phase":"PHASE3","title":"AZD1222 Vaccine for the Prevention of COVID-19","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2020-09-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05060861","phase":"","title":"Safety, Efficacy of Chadox1 Ncov-19 Vaccine: Rapid Systematic Review and Meta Analysis","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-06-01","conditions":"ChAdOx1 nCoV-19 Vaccine","enrollment":2000},{"nctId":"NCT04988048","phase":"PHASE2","title":"Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina","status":"UNKNOWN","sponsor":"Ministry of Public Health, Argentina","startDate":"2021-08-03","conditions":"COVID-19 VACCINE, Covid19","enrollment":1760},{"nctId":"NCT05059106","phase":"PHASE2, PHASE3","title":"EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19","status":"UNKNOWN","sponsor":"Federal University of Espirito Santo","startDate":"2021-06-01","conditions":"SARS-CoV-2","enrollment":29637},{"nctId":"NCT04907331","phase":"PHASE2","title":"Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2","status":"UNKNOWN","sponsor":"Medical University Innsbruck","startDate":"2021-05-10","conditions":"SARS-CoV2 Infection","enrollment":3000},{"nctId":"NCT05027672","phase":"PHASE2","title":"Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines.","status":"UNKNOWN","sponsor":"Ministerio de Salud de Ciudad Autónoma de Buenos Aires","startDate":"2021-07-30","conditions":"COVID-19 Vaccines","enrollment":348},{"nctId":"NCT04962906","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes","status":"COMPLETED","sponsor":"Ministerio de Salud de Ciudad Autónoma de Buenos Aires","startDate":"2021-07-05","conditions":"COVID-19 Vaccines","enrollment":192},{"nctId":"NCT04983537","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes in an Elderly Population","status":"UNKNOWN","sponsor":"Ministerio de Salud de Ciudad Autónoma de Buenos Aires","startDate":"2021-07-26","conditions":"COVID-19 Vaccines","enrollment":120},{"nctId":"NCT04961385","phase":"","title":"Immunogenicity of the ChAdox1 n CoV-19 Vaccine With 12-dose Vial","status":"COMPLETED","sponsor":"Bangkok Metropolitan Administration Medical College and Vajira Hospital","startDate":"2021-04-01","conditions":"Covid19, Vaccine, Immunogenicity","enrollment":60},{"nctId":"NCT04794946","phase":"NA","title":"Safety and Efficacy of a Non-replicating ChAdOx1 Vector Vaccine AZD1222 (COVISHIELD), for Prevention of COVID-19 in Patients With Liver Cirrhosis","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2021-03-19","conditions":"Liver Cirrhosis","enrollment":2200},{"nctId":"NCT04730895","phase":"PHASE1, PHASE2","title":"Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety.","status":"UNKNOWN","sponsor":"Kafrelsheikh University","startDate":"2021-07","conditions":"Covid19 Vaccine","enrollment":360},{"nctId":"NCT04885764","phase":"PHASE2, PHASE3","title":"Profiling Antibody Status and Vaccine Effectiveness in Post Vaccination With SARS CoV2 in Ain Shams University","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2021-02-23","conditions":"Covid19","enrollment":4000},{"nctId":"NCT04769258","phase":"","title":"Effectiveness and Safety of COVID-19 Vaccine in Patients With IBD Treated With Immunomodulatory or Biological Drugs (ESCAPE-IBD)","status":"UNKNOWN","sponsor":"Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)","startDate":"2021-03-01","conditions":"Inflammatory Bowel Diseases","enrollment":1380},{"nctId":"NCT04444674","phase":"PHASE1, PHASE2","title":"COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2020-06-24","conditions":"Coronavirus","enrollment":2130},{"nctId":"NCT04536051","phase":"PHASE3","title":"A Study of a Candidate COVID-19 Vaccine (COV003)","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2020-06-02","conditions":"Coronavirus","enrollment":10300},{"nctId":"NCT03105115","phase":"NA","title":"Effect of Intrathecal Fentanyl on Spinal Anesthesia During Dexmedetomidine Infusion","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2017-05-25","conditions":"Anesthesia, Spinal","enrollment":56},{"nctId":"NCT03092076","phase":"PHASE1","title":"The Impact of Genotype on Pharmacokinetics and Antiplatelet Effects of Ticagrelor in Healthy Chinese","status":"COMPLETED","sponsor":"Guangdong Provincial People's Hospital","startDate":"2015-05-20","conditions":"Healthy","enrollment":51}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"BACK PAIN"},{"count":5,"reaction":"DRY SKIN"},{"count":5,"reaction":"NASOPHARYNGITIS"},{"count":5,"reaction":"SKIN ULCER"},{"count":4,"reaction":"ABDOMINAL DISTENSION"},{"count":4,"reaction":"CONSTIPATION"},{"count":4,"reaction":"DIARRHOEA"},{"count":4,"reaction":"GASTROINTESTINAL DISORDER"},{"count":4,"reaction":"NEUROPATHY PERIPHERAL"},{"count":4,"reaction":"RASH PAPULAR"}],"_approvalHistory":[],"publicationCount":1231,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["COVISHIELD"],"phase":"phase_3","status":"active","brandName":"ChAdOx1 nCoV-19","genericName":"ChAdOx1 nCoV-19","companyName":"EuBiologics Co.,Ltd","companyId":"eubiologics-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"ChAdOx1 nCoV-19 is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene into cells to trigger an immune response against COVID-19. Used for COVID-19 prevention in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}